Literature DB >> 22044873

Association of biomarkers and depressive symptoms in schizophrenia.

Cristiano Souza Noto1, Ary Gadelha, Síntia Iole Belangero, Marília Arruda Cardoso Smith, Bianca W de Aguiar, Bruna Panizzuti, Jair de Jesus Mari, Clarissa Severino Gama, Rodrigo Affonseca Bressan, Elisa Brietzke.   

Abstract

Emergence of depressive symptoms in schizophrenia results in a deteriorating course and poor prognosis. Schizophrenia and depressive disorder are both associated with low levels of brain-derived neurotrophic factor (BDNF) and with a longstanding low grade inflammatory state. The objective of this study is to analyze the relationship between these serum biomarkers and depressive and psychotic symptoms in schizophrenic patients. Thirty-nine individuals diagnosed with schizophrenia or schizoaffective disorder by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), assessed by Structured Clinical Interview for DSM-IV (SCID), were included. Interviews were conducted with The Positive and Negative Syndrome Scale (PANSS) and The Calgary Depression Scale for Schizophrenia (CDSS). Blood samples were collected for determination of BDNF, IL-1beta, IL-6, IL-8, IL-10, IL-12 and TNF-alpha measurements. Positive correlations between BDNF and CDSS and between IL-1beta and severity in PANSS scores were found. BDNF levels were not correlated with any cytokine or with PANSS scores. The results of this study suggest that depressive and psychotic symptoms may be associated with different profiles of biomarkers in the association between schizophrenia and depression.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22044873     DOI: 10.1016/j.neulet.2011.10.042

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind, placebo-controlled study.

Authors:  Jennifer M Loftis; Clare J Wilhelm; Marilyn Huckans
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

2.  Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.

Authors:  Cristiano Noto; Vanessa Kiyomi Ota; Eduardo S Gouvea; Lucas B Rizzo; Leticia M N Spindola; Pedro H S Honda; Quirino Cordeiro; Sintia Iole Belangero; Rodrigo Affonseca Bressan; Ary Gadelha; Michael Maes; Elisa Brietzke
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

Review 3.  Depression and Cardiovascular Disease: The Viewpoint of Platelets.

Authors:  Patrizia Amadio; Marta Zarà; Leonardo Sandrini; Alessandro Ieraci; Silvia Stella Barbieri
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

4.  Concordance of Immune-Related Markers in Lymphocytes and Prefrontal Cortex in Schizophrenia.

Authors:  Eleonora Gatta; Vikram Saudagar; Jenny Drnevich; Marc P Forrest; James Auta; Lindsay V Clark; Henry Sershen; Robert C Smith; Dennis R Grayson; John M Davis; Alessandro Guidotti
Journal:  Schizophr Bull Open       Date:  2021-02-06

5.  Gender Differences of Schizophrenia Patients With and Without Depressive Symptoms in Clinical Characteristics.

Authors:  Ruimei Liu; Xinyu Fang; Lingfang Yu; Dandan Wang; Zenan Wu; Chaoyue Guo; Xinyue Teng; Juanjuan Ren; Chen Zhang
Journal:  Front Psychiatry       Date:  2022-01-13       Impact factor: 4.157

6.  Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia.

Authors:  Yuxuan Wu; Xiangdong Du; Ruchang Yang; Yan Yue; Ruijie Peng; Siqi Wu; Haitao Wang; Yue Zhou; Xiaojia Fang; Nian Yuan; Ronghua Li; Jun Zhang; Siyun Zou; Xueli Zhao; Xiaoli Lyu; Zhe Li; Xiaobin Zhang; Xiangyang Zhang
Journal:  Front Psychiatry       Date:  2022-06-09       Impact factor: 5.435

Review 7.  Cytokine Alterations in Schizophrenia: An Updated Review.

Authors:  Sara Momtazmanesh; Ameneh Zare-Shahabadi; Nima Rezaei
Journal:  Front Psychiatry       Date:  2019-12-06       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.